Differences

This shows you the differences between two versions of the page.

--- proceedings:2023_igorr21 [2025/12/11 10:35] – Bruno Baumeister
+++ proceedings:2023_igorr21 [2025/12/17 09:39] (current) – Bruno Baumeister
@@ Line 1: / Line 1: @@
-====== IGORR 21 (collaboration with TRTR) - Maryland, USA - June 2023 ======
+====== IGORR 21 (collaboration with TRTR, support by IAEA) - Maryland, USA - June 2023 ======
 {{:proceedings:2023_igorr21:53003352462_e63dd126b2_b.jpg?direct |}}
 ^
@@ Line 86: / Line 86: @@
 |05| {{ :proceedings:2023_igorr21:s12-05-ashy-simulation-assisted-engineering-sae-applied-to-new-b.pdf |Simulation Assisted Engineering Applied to New Builds}}|O. Ashy (WSC, USA)|
 |**__Session 13: NRC Plenary Session (Wednesday 21 June 2023)__**|||
-|01| {{ :proceedings:2023_igorr21:s13-01-borromeo-non-power-production-and-utilization-facility-li.pdf |Josh Borromeo – Presentation}}|J. Borromeo (U.S. Nuclear Regulatory Commission, USA)|
+|01| {{ :proceedings:2023_igorr21:s13-01-borromeo-non-power-production-and-utilization-facility-li.pdf |Non-Power Production and Utilization Facility Licensing Branch – Overview}}|J. Borromeo (U.S. Nuclear Regulatory Commission, USA)|
-|02| {{ :proceedings:2023_igorr21:s13-02-tate-non-power-production-and-utilization-facility-ov.pdf |Travis Tate – Presentation}}|T. Tate (U.S. Nuclear Regulatory Commission, USA)|
+|02| {{ :proceedings:2023_igorr21:s13-02-tate-non-power-production-and-utilization-facility-ov.pdf |Non-Power Production and Utilization Facility Oversight Branch - Overview}}|T. Tate (U.S. Nuclear Regulatory Commission, USA)|
 |**__Session 14: Operations and Maintenance 3 (Wednesday 21 June 2023)__**|||
 |01| {{ :proceedings:2023_igorr21:s14-01-bonvalet-upgrade-of-an-overhead-crane-in-the-cabri-nuclea.pdf |Upgrade of an overhead crane in the nuclear research reactor CABRI}} \\ {{ :proceedings:2023_igorr21:s14-01-bonvalet-upgrade-of-an-overhead-crane-in-the-cabri-nuclea-paper.pdf|Paper}}|D. Bonvalet (French Atomic and Alternative Energies Commission, France)|
@@ Line 96: / Line 96: @@
 |01| {{ :proceedings:2023_igorr21:s15-01-oliveri-incluseion-of-gender-minorities-in-nuclear.pdf |Inclusion of Gender Minorities}}|A. S. Oliveri (Reed College, USA)|
 |**__Session 16: Medical Isotope Production Panel (Thursday 22 June 2023)__**|||
-|01| {{ :proceedings:2023_igorr21:s16-01-jones-trtr-industry-collaboration-serva.pdf |Sarah Jones – Presentation}}|S. Jones (Serva Energy, USA)|
+|01| {{ :proceedings:2023_igorr21:s16-01-jones-trtr-industry-collaboration-serva.pdf |Industry and Test Reactors: Collaboration for Production of Medical Isotopes}}|S. Jones (Serva Energy, USA)|
-|02| {{ :proceedings:2023_igorr21:s16-02-bryan-production-of-medical-radioisotopes-at-ornl-trtr-ig.pdf |Chris Bryan – Presentation}}|C. Bryan (Oak Ridge National Laboratory, USA)|
+|02| {{ :proceedings:2023_igorr21:s16-02-bryan-production-of-medical-radioisotopes-at-ornl-trtr-ig.pdf |Production of Medical Radioisotopes at Oak Ridge National Laboratory}}|C. Bryan (Oak Ridge National Laboratory, USA)|
-|03| {{ :proceedings:2023_igorr21:s16-03-ruddock-medical-isotope-regulatory-considerations.pdf |Patrick Ruddock – Presentation}}|P. Ruddock (AtomVie Global Radiopharma, USA)|
+|03| {{ :proceedings:2023_igorr21:s16-03-ruddock-medical-isotope-regulatory-considerations.pdf |Medical Isotopes Regulatory Considerations}}|P. Ruddock (AtomVie Global Radiopharma, USA)|
 |**__Other presentations__**|||
 |01| {{ :proceedings:2023_igorr21:other-gibson-murr-overview.pdf |MURR Overview}}|R. Gibson (Missouri University of Science and Technology, USA)|
 |02| {{ :proceedings:2023_igorr21:other-hiebert-mutr-and-the-uranium-club.pdf |MUTR and the Uranium Club}}|M. E. Hiebert|
 </datatables>